A comprehensive new brain imaging study led by scientists at the Centre for Addiction and Mental Health (CAMH) has uncovered what researchers are describing as the most compelling and robust evidence to date that long COVID is directly associated with tangible damage to dopamine-releasing neurons within the human brain. Published in the scientific journal eBioMedicine, these striking findings could finally help explain a wide array of persistent, debilitating problems reported by millions of patients worldwide, including fatigue-related loss of motivation, slowed physical movement, and persistent cognitive and memory difficulties. Furthermore, this breakthrough discovery may fundamentally shift the medical landscape, pointing the way toward entirely new, targeted treatment strategies for a condition that has baffled clinicians for years.
Long COVID remains a widespread public health crisis, estimated to affect approximately five percent of the global population. In Canada alone, the condition impacts roughly two million individuals, casting a long shadow over their daily lives, professional pursuits, and personal well-being. The medical condition can involve a sprawling, unpredictable broad range of symptoms that stubbornly continue for at least three months after the initial acute COVID-19 infection has cleared. Among the most common and disruptive of these manifestations are neurological and psychological hurdles, including profound fatigue, cognitive impairment often referred to as "brain fog," memory retrieval problems, and persistently low mood or depression.
Despite how remarkably widespread and deeply disruptive long COVID continues to be for sufferers, there are currently virtually no approved, evidence-based treatments available on the market. This frustrating therapeutic vacuum exists in large part because medical scientists and clinical researchers still do not fully understand the intricate biological mechanisms unfolding inside the brain of an affected patient. Unlocking these underlying mysteries has become one of the top priorities for neurological researchers across the globe, making the new CAMH study a major milestone in the ongoing effort to decode the post-viral syndrome.
Brain Scans Reveal Significant Changes in the Dopamine System
To peel back the layers of this complex neurological puzzle, the research team employed advanced neuroimaging technology for their study. Specifically, they utilized positron emission tomography (PET), a sophisticated imaging technique capable of measuring precise biological, chemical, and metabolic activity inside the living human brain. By leveraging this tool, the scientists were able to examine a well-established molecular marker intimately associated with the health, density, and overall integrity of dopamine neurons in individuals suffering from long COVID. They then meticulously compared these neuroimaging results against a control group of healthy participants to establish a clear baseline of comparison.
The results of the PET scans were both revealing and stark. The researchers discovered substantially lower levels of the dopamine neuron health marker in people with long COVID across all major anatomical areas of the striatum. The striatum is a critical cluster of interconnected deep brain regions that plays a master regulatory role in human motivation, physical movement, and higher-level cognitive thinking. The observation of lower marker levels strongly suggests a significantly reduced density of functional dopamine nerve terminals within these vital pathways, effectively starving the brain circuits of the chemical signals they need to operate smoothly.
Crucially, the study also uncovered distinct, localized patterns of marker loss that closely mapped onto specific symptoms reported by the patients. For instance, lower marker levels specifically located within the ventral striatum were linked directly to a greater loss of motivation and drive in patients. Meanwhile, reductions observed in the dorsal putamen were closely associated with slower physical movement, and lower levels found within the caudate putamen were connected with persistent memory difficulties.
"Our findings provide compelling evidence that long COVID involves the loss of dopamine-releasing neurons," says Dr. Jeffrey Meyer, Senior Scientist at the Brain Health Imaging Centre, Canada Research Chair, and senior author of the influential study. "This kind of injury is well known to produce symptoms like lack of motivation and motor slowing, and may contribute to memory difficulties in other neurological conditions. Our results suggest a similar process is occurring in long COVID."
Earlier Research Pointed to Brain Inflammation
These fresh findings do not exist in a vacuum; rather, they build solidly upon previous pioneering work conducted by the very same CAMH research team. In earlier studies, these scientists revealed that people suffering from long COVID exhibit unusually high levels of neuroinflammation—or inflammation within the brain tissue. Notably, that immune-mediated inflammation appeared to be especially pronounced and concentrated precisely within the brain regions containing large numbers of dopamine-releasing neurons.
The convergence of these two lines of scientific inquiry paints a vivid picture of how the virus’s lingering effects manifest neurologically. Inflammation is known to be a powerful biological disruptor and a primary driver of cellular injury in various disease states, and the brain is no exception to this rule.
"We know that inflammation can injure dopamine neurons," explains Dr. Meyer, drawing a direct line between the team’s sequential discoveries. "While our earlier research showed high levels of inflammation in those regions, this study provides direct evidence that the dopamine neuron marker is reduced in the same regions—and that this loss correlates with patients’ symptoms."
Taken together, these two major studies strongly suggest a causal, destructive connection between persistent brain inflammation and subsequent structural damage involving the delicate dopamine system. It transforms vague complaints of post-viral malaise into a measurable, localized neurobiological phenomenon.
A New Direction for Long COVID Treatment
The implications of these results extend far beyond academic curiosity; they have the profound potential to alter how the global medical and scientific communities approach both the fundamental biology and the clinical treatment of long COVID. Historically, a vast majority of previous research efforts have centered narrowly on general inflammation in the brain and broad changes in systemic immune activity. By comparison, very few clinical trials or targeted interventions have focused directly on protecting, repairing, or supporting dopamine-releasing neurons.
"These results indicate that long COVID is, at least in part, a disorder of the brain’s dopamine system," adds Dr. Meyer. "This suggests that repurposing medications that augment the function of dopamine-releasing neurons, including dopamine precursors and inhibitors of dopamine metabolism, could be a promising approach."
For the millions of people living with the daily reality of long COVID, the findings may also provide a deeply validating biological explanation for symptoms that have historically been notoriously difficult to measure, quantify, or prove from the outside. Because standard blood tests and routine neurological screenings often return normal results, patients have frequently faced skepticism from employers, insurers, and even members of the medical community.
"For five years I have been seeking answers on what happened to me after I contracted COVID in 2021," says Susan Deuville, a lived experience research advisor who worked alongside Dr. Meyer. "It was a crushing loss of the life I had and the person I was before. The research of Dr. Meyer brings hope. It also validates what long COVID sufferers have always known—long COVID is real and the effects are devastating."
Clinical Trial Planned to Target Dopamine Function
Capitalizing on the momentum of these results, the research team is not resting on its laurels. Preparations are already underway to launch a pioneering clinical trial in the upcoming couple of months. This upcoming study will directly target dopamine function in human subjects suffering from long COVID, with the overarching goal of determining whether medically modifying and supporting dopamine activity can effectively improve memory retrieval, restore motivation, and alleviate the crushing fatigue that defines the condition.
The upcoming trial will be conducted in close collaboration with the University Health Network (UHN), operating as part of an institutional partnership between the hospitals designed specifically to bridge the stubborn historical gap between mental and physical health care. Financial support for the foundational research was provided by the Canadian Institutes of Health Research (CIHR).
